エピソード

  • Why Antidepressants Take Weeks to Work

    Why Antidepressants Take Weeks to Work
    2026/10/18
    Explore serotonin transporters, receptor adaptations, and the differences between immediate medication effects and delayed clinical improvement. Explain why antidepressant response cannot be reduced to a simple chemical imbalance.
    続きを読む 一部表示
    5 分
  • Beyond Fentanyl: The Rise of Synthetic Opioids Ten Times More Potent

    Beyond Fentanyl: The Rise of Synthetic Opioids Ten Times More Potent
    2026/10/15
    A new class of synthetic opioids known as orphine analogues has been detected in illicit drug supplies across 22 American states, raising concerns about the next evolution of the opioid crisis. Some of these compounds have demonstrated pharmacological potency substantially greater than fentanyl, while conventional drug screening methods may fail to identify them. We examine how these substances affect the brain, why respiratory depression is so dangerous, and what makes their detection and treatment particularly challenging. We also explore the implications for emergency medicine, forensic toxicology, and the future of opioid pharmacology.
    続きを読む 一部表示
    3 分
  • Why Antidepressants Sometimes Stop Working: The Science Behind the Loss of Response

    Why Antidepressants Sometimes Stop Working: The Science Behind the Loss of Response
    2026/10/11
    Antidepressants influence neurotransmission relatively quickly, yet meaningful clinical improvement often takes longer. This episode explores receptor signaling, neural adaptation, stress circuitry, and neuroplasticity in depression treatment. Discover why changes in brain function are more complicated than the familiar chemical-imbalance explanation.
    続きを読む 一部表示
    4 分
  • When Antipsychotics Aren’t the Answer: The Medical Illness That Can Look Like Psychosis

    When Antipsychotics Aren’t the Answer: The Medical Illness That Can Look Like Psychosis
    2026/10/07
    Hallucinations, paranoia, agitation, and bizarre behavior can reasonably lead clinicians toward antipsychotic treatment, but what happens when the underlying illness isn’t primarily psychiatric? Anti-NMDA receptor encephalitis can initially resemble a severe psychiatric disorder before neurological symptoms emerge. This episode examines the diagnostic clues that can change the entire treatment strategy.
    続きを読む 一部表示
    3 分
  • Why Do SSRIs Take Weeks to Work If They Change Serotonin Within Hours?

    Why Do SSRIs Take Weeks to Work If They Change Serotonin Within Hours?
    2026/10/04
    SSRIs begin altering serotonin signaling within hours, yet people with depression or anxiety are often told that meaningful improvement may take weeks. Why does the brain respond so slowly if the medication begins working almost immediately? The answer reveals why the familiar idea of antidepressants simply “correcting a chemical imbalance” is far too simplistic. This episode explores serotonin transporters, receptor adaptation, neural plasticity, and the gradual biological changes that may contribute to antidepressant effects. It also explains why an SSRI can be pharmacologically active long before a person notices a meaningful psychological difference.
    続きを読む 一部表示
    4 分
  • Beyond the Daily Pill: The Injection Shaking Up Bipolar Treatment

    Beyond the Daily Pill: The Injection Shaking Up Bipolar Treatment
    2026/09/13
    A new study published in The American Journal of Psychiatry analyzed electronic health records from 2,086 individuals with bipolar disorder in Hong Kong treated between 2004 and 2023. While long-acting injectable antipsychotics (LAIAs) are already widely recognized for treating schizophrenia, robust comparative guidance for bipolar disorder has historically been limited. The researchers found that patients receiving LAIAs had a significantly lower risk of psychiatric hospitalization compared to those on traditional oral antipsychotics. In addition, the injectable treatments were tied to a reduced recurrence rate of manic and mixed episodes, offering compelling evidence for their expanded clinical role.
    続きを読む 一部表示
    3 分
  • A Simpler Way to Ease OCD When Bipolar Is Also in the Picture

    A Simpler Way to Ease OCD When Bipolar Is Also in the Picture
    2026/09/10
    Many people live with both bipolar disorder and obsessive-compulsive symptoms. The usual medicines for OCD can make bipolar moods swing more wildly. A new study points to a different option that may help without that risk.
    続きを読む 一部表示
    2 分
  • The FDA Is Fast-Tracking Psychedelics. Noribogaine Is the Test Case That Is Not a Trip.

    The FDA Is Fast-Tracking Psychedelics. Noribogaine Is the Test Case That Is Not a Trip.
    2026/09/07
    After an executive order pushing HHS to speed mental-health treatments, the FDA issued priority vouchers for psilocybin in depression and methylone in PTSD and cleared the first U.S. trial of an ibogaine-related drug. That compound is noribogaine, aimed at alcohol use disorder, and its developers argue it is not hallucinogenic. The scientific question is no longer whether Washington is interested. It is whether cardiac risk, blinding, and psychotherapy can survive a real review.
    続きを読む 一部表示
    3 分